Table 2. Key prospective and retrospective studies for transcatheter arterial chemoembolization in metastatic colorecal cancer.
| Study (year) | Analysis | Regimen | Patients (n) | Ref. |
|---|---|---|---|---|
| TACE as salvage therapy in chemorefractory mCRC | ||||
| Tellez et al. (1998) | Prospective | TACE (cisplatin, doxorubicin + mitomycin C) | 30 | [47] |
| Bavisotto et al. (1999) | Prospective | Alternating TACE (cisplatin) and PCI-5FU | 27 | [48] |
| Geschwind et al. (2006) | Prospective | TACE (cisplatin, doxorubicin + mitomycin C) | 21 | [51] |
| Albert et al. (2011) | Retrospective | TACE (cisplatin, doxorubicin + mitomycin C) | 121 | [52] |
| Nishiofuku et al. (2013) | Prospective | TACE (cisplatin) | 24 | [53] |
| Vogl et al. (2009) | Prospective | TACE (mitomycin C alone vs mitomycin C + gemcitabine vs mitomycin C + irinotecan) | 243 vs 153 vs 67 | [54] |
| Neoadjuvant TACE in mCRC | ||||
| Vogl et al. (2003) | Prospective | TACE (mitomycin C) | 162 | [55] |
5FU: 5-fluorouracil; mCRC: Metastatic colorectal cancer; PCI: Protracted continuous infusion; TACE: Transarterial chemoembolization.